Mortality, Second Stroke Risk Up for Initially Stable Survivors

This article originally appeared here.
Share this content:
Mortality, Second Stroke Risk Up for Initially Stable Survivors
Mortality, Second Stroke Risk Up for Initially Stable Survivors

MONDAY, July 24, 2017 (HealthDay News) -- Risk of a second stroke or transient ischemic attack (TIA) remains considerable for at least five years after the first event, according to a study published online July 24 in CMAJ, the journal of the Canadian Medical Association.

Jodi Edwards, Ph.D., of the Sunnybrook Health Sciences Center in Toronto, and colleagues collected data on 26,366 stroke and TIA survivors without recurrent stroke, myocardial infarction, all-cause admission to hospital, admission to an institution, or death in the first 90 days after discharge. The researchers compared them with 263,660 healthy individuals matched by age, gender, and region. The team assessed the primary composite outcome of death, stroke, myocardial infarction, or admission to long-term or continuing care.

The investigators found that risk the primary outcome was increased at one, three, and five years (hazard ratios [HRs], 2.4, 2.2, and 2.1, respectively). The risks were highest for recurrent stroke at one year (HR, 6.8), continuing to five years (HR, 5.1), and for admission to an institution (HR, 2.1).

"Patients who survive stroke or TIA without early complications are typically discharged from secondary stroke prevention services. However, these patients remain at substantial long-term risk, particularly for recurrent stroke and admission to an institution," the authors write. "Novel approaches to prevention, potentially embedded in community or primary care, are required for long-term management of these initially stable but high-risk patients."

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths